A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy.
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms REVEL
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 21 Sep 2016 This study was completed in Sweden (end date: 2016-08-01), according to European Clinical Trials Database record.
- 02 Sep 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History